Abstract
Purpose. It has been reported that grapefruit juice (GJ) causes a pharmacokinetic interaction with many drugs after co-ingestion. It is postulated that the substances in GJ may inhibit the first-pass metabolism during the intestinal absorption process. In recent years, several furanocoumarin derivatives that inhibit P450 activity in intestinal microsomes were isolated from GJ. In this study, we report the effects of the furanocoumarin derivatives in GJ on the nifedipine (NFP) pharmacokinetics in rats.
Methods. Three furanocoumarin derivatives (bergaptol [BT], bergamottin [BG], and 6′,7′-dihydroxybergamottin [DHB]) found in GJ were used in this study. Each furanocoumarin was reconstituted in orange juice at the same concentration as in the GJ. Two milliliters of each sample was administered into the rat duodenum. After 30 min, NFP was intraduodenally administered at a dose of 3 mg/kg body weight. The NFP concentrations in the plasma samples were determined by HPLC.
Results. A significant increase in the AUC of NFP was observed only in the rats administered BG; 1.5 times that of the control group. The result was quite identical with that of the group that was administered GJ. BT and DHB had no significant effects on the NFP pharmacokinetics.
Conclusions. The results strongly suggested that BG in GJ might be the substance that elevates the NFP plasma concentrations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
D. G. Bailey, J. Malcolm, O. Arnold, and J. D. Spence. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 46:101-110 (1998).
U. Fuhr. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf. 18:251-272 (1998).
H. Takanaga, A. Ohnishi, H. Matsuo, and Y. Sawada. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull. 21:1062-1066 (1998).
K. Fukuda, T. Ohta, Y. Oshima, N. Ohashi, M. Yoshikawa, and Y. Yamazoe. Specific CYP3A4 inhibitors in grapefruit juice: Furocoumarin dimers as components of drug interaction. Pharmacogenetics 7:391-396 (1997).
D. J. Edwards, F. H. Bellevue III, and P. M. Woster. Identification of 6′, 7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab. Dispos. 24:1287-1290 (1996).
F. Buiarelli, G. P. Cartoni, F. Coccioli, and T. Leone. Analysis of bitter essential oils from orange and grapefruit by high-performance liquid chromatography with microbore columns. J. Chromatogr. A 730:9-16 (1996).
P. Schmiedlin-Ren, D. J. Edwards, M. E. Fitzsimmons, K. He, K. S. Lown, P. M. Woster, A. Rahman, K. E. Thummel, J. M. Fisher, P. F. Hollenberg, and P. B. Watkins. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 25: 1228-1233 (1997).
L. Q. Guo, K. Fukuda, T. Ohta, and Y. Yamazoe. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos. 28:766-771 (2000).
K. He, K. R. Iyer, R. N. Hayes, M. W. Sinz, T. F. Woolf, and P. F. Hollenberg. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 11:252-259 (1998).
K. Yamaoka and T. Nakagawa. A nonlinear least squares program based on differential equations, MULTI (RUNGE), for microcomputers. J. Pharmacobiodyn. 6:595-606 (1983).
K. Yamaoka, T. Nakagawa, and T. Uno. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:547-558 (1978).
H. L. Bonkovsky, H. P. Hauri, U. Marti, R. Gasser, and U. A. Meyer. Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by Phenobarbital. Gastroenterology 88:458-467 (1985).
O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
B. Ameer and R. A. Weintraub. Drug interactions with grapefruit juice. Clin. Pharmacokinet. 33:103-121 (1997).
D. G. Bailey, J. D. Spence, C. Munoz, and J. M. O. Arnold. Interaction of citrus juices with felodipine and nifedipine. Lancet 337:268-269 (1991).
J. S. Grundy, L. A. Eliot, K. M. Kulmatycki, and R. T. Foster. Grapefruit juice and orange juice effects on the bioavailability of nifedipine in the rat. Biopharm. Drug. Dispos. 19:175-183 (1998).
A. Soldner, U. Christians, M. Susanto, V. J. Wacher, J. A. Silverman, and L. Z. Benet. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm. Res. 16:478-485 (1999).
D. G. Bailey, J. H. Kreeft, C. Munoz, D. J. Freeman, and J. R. Bend. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′-dihydroxybergamottinin humans. Clin. Pharmacol. Ther. 64:248-56 (1998).
D. J. Edwards, M. E. Fitzsimmons, E. G. Schuetz, K. Yasuda, M. P. Ducharme, L. H. Warbasse, P. M. Woster, J. D. Schuetz, and P. Watkins. 6′,7′-dihydroxybergamottinin grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin. Pharmacol. Ther. 65:237-244 (1999).
W. Tassaneeyakul, L. Q. Guo, K. Fukuda, T. Ohta, and Y. Yamazoe. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch. Biochem. Biophys. 378:356-63 (2000).
A. Ohnishi, H. Matsuo, S. Yamada, H. Takanaga, S. Morimoto, Y. Shoyama, H. Ohtani, and Y. Sawada. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br. J. Pharmacol. 130:1369-1377 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mohri, K., Uesawa, Y. Effects of Furanocoumarin Derivatives in Grapefruit Juice on Nifedipine Pharmacokinetics in Rats. Pharm Res 18, 177–182 (2001). https://doi.org/10.1023/A:1011028401189
Issue Date:
DOI: https://doi.org/10.1023/A:1011028401189